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ess: cmicheletto@ulss2Summary Aspirin-induced asthma (AIA) is a syndrome characterized by intoler-
ance to aspirin (ASA), nasal polyps and bronchial asthma, the metabolic shift of
arachidonic acid towards the lipoxygenase pathway and hyper-production of
cysteinyl-leukotrienes (cys-LTs) being the current pathogenetic hypothesis. The
research for both sensitive indicators and safe diagnostic tests is still attracting. Aim
of the study was to measure changes in urinary LTE4 excretion and in nasal function
(Resistance—Req, and Volume—Vol, assessed by acoustic rhinomanometry (AR))
following a nasal provocation test (NPT) with ASA:LTE4 measurements have been
never previously used to our knowledge for assessing nasal responsiveness to ASA.
Methods: After written consent, 118 mild-to-moderate asthmatics (48 males, mean
age 41.8 years711.9SD, range 25–70 years; basal FEV1 ¼ 80.1%pred.75.8SD) under-
went NPT by nasal instillation of ASA (total maximal dose 25mg). Spirometry,
acoustic rhinomanometry (AR; TM Hood Lab., USA) and urinary LTE4 (pg/mg
creatinine; Cayman Chemical, MI, USA) were measured in baseline and 2 h after the
ASA challenge.
Statistics: t-Test between means7SD, assuming Po0:05, and linear regression
between all variables considered.
Results: In 67 ASA-intolerant asthmatics, FEV1 did not change significantly following
NPT (81.7% pred.75.1SD in baseline, 80.5% pred.74.1 after NPT, P ¼ ns) even in the
presence of a significant decrease of Vol (11.3 cm374.1SD in baseline, 5.9 cm374.2SD
after NPT, P ¼ 0:003), a substantial increase of Req (0.88 cmH2O/l/min70.11SD in
baseline, 2.41 cmH2O/l/min70.77 after NPT, P ¼ 0:002), and urinary LTE4 excretion
(433.0 pg/mg7361.7 in bsln, 858.0 pg/mg7471.6 90min after NPT with L-SA,
P ¼ 0:04). NPT did not affect FEV1 also in 51 ASA-tolerant asthmatics (89.7%
pred.76.9 in bsln, 86.6% pred.74.3 after NPT), but in these subjects also Vol (from
14.9 cm374.2SD to 14.6 cm373.8SD), Req (0.38 cmH2O/l/min70.14 in bsln,Elsevier Ltd. All rights reserved.
6712229; fax: +39 045 6712544.
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Changes in urinary LTE4 and nasal functions 21450.26 cmH2O/l/min70.2 after NPT, P ¼ ns), and urinary LTE4 (333.1 pg/mg7202.8 in
bsln, 318.0 pg/mg7198.7 after NPT, P ¼ ns) remained unchanged. Only pre-NPT
LTE4 values proved related to pre-NPT Req and Vol values (r ¼ 0:54 and r ¼ 0:71,
respectively), but not to patients’ age (R ¼ 0:05), and basal FEV1 (r ¼ 0:01).
Conclusions: In ASA-intolerant patients, NPTwith lysine-aspirin (L-ASA) only induces
a substantial nasal obstruction and enhances urinary LTE4 excretion in the absence of
any significant bronchial obstruction. Nasal ASA challenge proves a test absolutely
safe for asthma patients suspected of ASA intolerance. Measures of urinary LTE4
excretion contributed significantly to magnify the discriminant and the diagnostic
value of NPT.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Aspirin-induced asthma (AIA) is a clinical syndrome
characterized by acute airway reactions to aspirin
(ASA) or other non-steroidal anti-inflammatory
drugs (NSAIDS), and nasal polyps.1 After ingestion
of ASA, asthmatic patients with AIA have attacks of
bronchospasm that are usually accompanied by
symptoms of nasal congestion, mucous secretion
and/or skin reactions, such as urticaria.
Watery rhinorrhea and nasal obstruction, leading
to frequent development of nasal polyps, usually
precede the occurrence of asthma and ASA intol-
erance for months or years.2 Aggressive nasal
polyps and asthma run a protracted course, despite
the avoidance of ASA and cross-reacting drugs. AIA
is difficult to treat and frequently these patients
require therapy with systemic corticosteroids to
control symptoms.3
The precise mechanism underlying this non-
immunological hypersensitivity still remains to be
clarified; however, it has been assumed that the
power of these pharmacological agents in provok-
ing asthma is related to their activity as inhibitors
of cyclooxygenase (COX).4–6 The most recent
hypothesis is suggesting that the genetic predis-
position to the up-regulation of cysteinyl-leuko-
trienes (cys-LTs) pathway could be related to an
overactive expression of LTC4 synthase.
7
Patients with AIA are also characterized by lower
production of prostaglandin E2 (PGE2) rather than
ASA-tolerant patients8,9 and that this alteration in
PGE2 production is probably due to an inadequate
COX-2 regulation.10
Even in stable clinical conditions, AIA patients
have an increased basal production of cys-LTs (such
as urinary LTE4).
11–13 They are also characterized by
a significant increase in urinary LTE4 excretion
following ASA ingestion14–16 and following ASA
inhalation16,17: other peculiar features of these
patients are their higher levels of urinary LTE4 and
LTB4 glucoronide (a chemotactic factor for eosino-phils and neutrophils) following the intravenous
ASA challenge.18
The research for both sensitive indicators and
safe diagnostic tests is still attracting. Nasal
provocation test (NPT) with lysine-aspirin (L-ASA)
has been introduced a few years ago for assessing
AIA also in patients with instable asthma19: the test
has been described as a highly specific and sensitive
one, but negative results do not exclude possible
intolerance to ASA. More recently, the acoustic
rhinomanometry (AR) has been suggested as the
most helpful diagnostic procedure for NPT with
L-ASA, its use being less limited than the anterior
rhinomanometry by the presence of nasal polyps
and nasal obstructions.20,21 Measurements of ur-
inary LTE4 collected before and after the challenge
were never associated to our knowledge to the NPT
test up to now.
Aim of the present study was to measure changes
in urinary LTE4 and nasal function assessed by AR
induced in mild-to-moderate asthmatics by a nasal
challenge with ASA.Materials and methods
Subjects and design
After written consent, 121 mild to moderate ever
non-smoker asthmatics were initially screened to
undergo a NPTwith L-ASA. Patients performed NPT
for a suspicious of AIA and/or for a history of nasal
polyps, or chronic rhinitis. As the test should not be
performed in the presence of the total obstruction
of at least one nostril, the results of the AR
leaded to exclude three patients. Thus, 118/121
subjects entered the study (48 males, mean
age 41.8y711.9SD, range 25–70 years; basal
FEV1 ¼ 80.1%pred. 75.8SD) and performed the
NPT with L-ASA after having stopped their medica-
tions (oral antihistamines and nasal corticosteroids
for 7 days, and nasal inhaled ant-H1 agents for at
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concomitant leukotriene receptor antagonists dur-
ing a 2-week washout period prior to the challenge.
Patients were also required to withhold any short-
acting b2-agonists and long-acting b2-agonists for at
least 6 and 48 h, respectively, prior to NPT.
None of the subjects were receiving systemic
corticosteroids or a 5-lipoxygenase inhibitor, and 99
out of the 118 asthmatic patients were using
inhaled steroids (median 500 mg equivalent to
BDP/day; range 400–1000 mg), in 56 cases asso-
ciated with long-acting b2-agonists. No patients
reported signs and symptoms of any infection of
upper or lower airways in the 4 weeks prior to the
study.
Acoustic rhinomanometry
Each patient performed the NPT according to the
method described by Casadevall and co-workers by
means of the AR18 This method consists in the
measurement of acoustic reflections from the nasal
cavity of a sound pulse created by a spark in a
sound tube connected to the nasal cavity via a
nosepiece. Unlike conventional rhinomanometry,
AR does not require generation of nasal flow, and
therefore its use is less limited by the presence of
nasal polyps and nasal obstruction. The response
was evaluated by the Eccovision Acoustic Rhinoma-
nometry System (TM Hood Laboratories, USA) with
the measurement of22:(1) calculated resistance, based on a tube with the
same area and laminar flow (Req, mmH2O/
l/min);(2) the total volume of the nostrils (Vol, cm3)
represents the nasal cavity volume in the
analysis segment;(3) the minimal cross-sectional area (cm2);
(4) its distance from the nosepiece (cm);Rhinomanometric measurements were per-
formed in an isolated space while the subject was
in apnoea after a non-forced expiration. The
rhinomanometer was calibrated daily with a cali-
bration tube provided by the manufacturer. The
analysis of data was performed using the Kwikstat
program (TM Texasoft).
Nasal provocation test with L-ASA
Baseline nasal function was measured with AR,
while the subjects were in a sitting position, then
80 ml of L-ASA solution (180mg/ml L-ASA) was
applied locally through nose droplets on theinferior nasal concha in both nostrils. The total
deposited dose of L-ASA was equivalent to 25mg of
acetylsalicylic acid. AR was then performed bilat-
erally every 10min for the next 2 h.
L-ASA was prepared freshly each day by dissolving
crystalline L-ASA in 0.9% sodium chloride to
produce a solution containing 180mg/ml.
NPT was considered positive when: nasal resis-
tance increased more than 40% in at least one
nostril as compared with the corresponding base-
line value; when the volume of one nostril
decreased more than 10% from baseline; both
parameters sustained for at least two consecutive
measurements, and were accompanied by clinical
symptoms persisting at least 30min. The dose of
ASA, the duration of the observation period, and
criteria for positivity of the test were established
on the basis of previous experiments.16–18
Simultaneously, pulmonary function (FEV1;
forced expiratory volume in 1 s) was measured by
using a computerized pneumotachograph (Master-
lab, Jaeger). We considered the maximal fall for
Req, Vol and FEV1 observed in the 2 h following the
NPT.Urinary LTE4
Urine samples were obtained before NPTwith L-ASA
and 2 h after the nasal instillation of L-ASA.
The time for urine collection was based on a
previous measure of urinary LTE4 after inhalation
challenge.16
Urinary LTE4 were measured by enzyme immu-
noassay (ACETM Competitive Enzyme Immunoassay,
Cayman Chemical, Ann Arbor, Mich, USA), as
reported by Pradelles et al.23
This assay is based on the competition between
LTE4 and an LTE4–acetylcholinesterase (AChE) con-
jugate (LTE4 tracer) for a limited amount of LTE4
antiserum. Because the concentration of the LTE4
tracer is held constant while the concentration of
LTE4 varies, the amount of LTE4 tracer that is able
to blind to the LTE4 antiserum will be inversely
proportional to the concentration of LTE4 in the
well. This antibody–LTE4 complex blinds to a mouse
monoclonal anti-rabbit IgG that has been previously
attached to the well. The plate is washed to
remove any unbound reagents and then Ellman’s
reagent (which contains the substrate to AChE) is
added to the well. This reagent consists of
acetylthiocholine and 5,50-dithio-bis-(2-nitroben-
zoic acid). Hydrolysis of acetylthiocholine by AChE
produces thiocholine. The non-enzymatc reaction
of thiocholine with 5,50-dithio-bis-(2-nitrobenzoic
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Figure 1 Urinary LTE4 in AIA patients in basal conditions
and after nasal provocation test with L-ASA.
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Changes in urinary LTE4 and nasal functions 2147acid) produces 5-thio-2-nitrobenzoic acid, which
has a strong absorbance at 412 nm. AChE has
several advantages over other enzymes commonly
used for enzyme immunoassays. Unlike horseradish
peroxidase, AChE does not self-inactivate during
turnover. In addition, the enzyme is highly stable
under the assay conditions, has a wide pH range (pH
5–10), and is not inhibited by common buffer salts
and preservatives. The product of this enzymatic
reaction has a distinct yellow colour and absorbs
strongly at 412 nm. The intensity of this colour,
determined spectrophotometrically, is proportional
to the amount of LTE4 tracer bound to the well,
which is inversely proportional to the amount of
free LTE4 present in the well. LTE4 was measured by
enzyme immunoassay on all samples according to
the manufacturers’ instructions and expressed in
pg/mg creatinine (pg/mg).
Statistical analysis
Mean values7SD obtained before and after NPT for
each variable were compared by t-test, and
Po0:05 was assumed as the lowest limit for the
statistical significance.
Linear regression was calculated for all variables
considered.0
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Figure 2 Urinary LTE4 in ASA-tolerant asthmatics in basal
conditions and after nasal provocation test with L-ASA.Results
In 67 subjects (the ASA-intolerant asthmatics), NPT
was discriminant for ASA intolerance: FEV1 did not
change significantly (81.7% pred.75.1SD in base-
line, 80.5% pred.74.1 after NPT, P ¼ ns) but
a substantial increase of Req (0.88 cmH2O/l/
min70.11SD in baseline, 2.41 cmH2O/l/min70.77
after NPT, P ¼ 0:002) and a corresponding signifi-
cant decrease of total volume (11.3 cm374.1SD in
baseline, 5.9 cm374.2SD after NPT, P ¼ 0:003) were
systematically recorded.
When compared to the corresponding basal
values, Req and Vol changes were discriminant for
ASA intolerance according to the criteria described
by Milewski et al.19 The diagnostic value of nasal
changes following NPT was further emphasized by
the changes observed in urinary LTE4 in the same
group of patients (433.0 pg/mg7361.7 in baseline,
858.0 pg/mg7471.6 after 2 h since the NPT with
L-SA, P ¼ 0:04) (Fig. 1).
In the remaining 51 subjects (such as the ASA-
tolerant asthmatics), NPT did not affect FEV1 at all
(89.7% pred.76.9 in bsln, 86.6% pred.74.3 after
NPT), but in these subjects both Req (0.38 cmH2O/
l/min70.14 in bsln, 0.26 cmH2O/l/min70.2 afterNPT, P ¼ ns), and Vol (from 14.9 cm3 7 4.2SD to
14.6 cm373.8SD) also unchanged. LTE4 excretion
was not affected by NPT (333.1 pg/mg7202.8 in
baseline, 318.0 pg/mg7198.7 after NPT, P ¼ ns)
and it represents a further confirmation of ASA
tolerance for these subjects (Fig. 2).
In baseline, when compared to ASA-tolerant
subjects, the ASA-intolerant ones were character-
ized by a higher mean level of urinary LTE4
excretion (433.0 pg/mg7361.7 and 333.1 pg/
mg7202.8 respectively; P ¼ 0:002), and by a worse
nasal function (Req ¼ 0.88 cmH2O/l/min70.11
vs 0.38 cmH2O/l/min70.14, P ¼ 0:003, and Vol ¼
11.3 cm374.1SD vs 14.9 cm374.2SD, P ¼ 0:05,
respectively).
While unrelated to age and basal FEV1 (r ¼ 0:05
and r ¼ 0:01, respectively), pre-NPT LTE4 proved
directly related to pre-NPT Req (r ¼ 0:54) and
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Figure 3 Linear regression between (a) pre-NPT Req values and pre-NPT LTE4 values (Y ¼ 0:3þ 0:001ðXÞ, r ¼ 0:54); (b)
pre-NPT Vol values and pre-NPT LTE4 values (Y ¼ 18:5þ 0:001ðXÞ, r ¼ 0:71); (c) post-NPT Req values and post-NPT
LTE4 values (Y ¼ 1:7þ 0:0005ðXÞ, r ¼ 0:19); (d) post-NPT Vol values and post-NPT LTE4 values (Y ¼ 9:620:004ðXÞ,
r ¼ 0:58).
C. Micheletto et al.2148inversely (more strictly) related to pre-NPT Vol
values (r ¼ 0:71). Post-NPT LTE4 proved unrelated
to corresponding post-NPT Req (r ¼ 0:19) even
though still inversely related to post-NPT Vol values
(r ¼ 0:59) (Fig. 3a–d).
NPT proved well tolerated in the whole popula-
tion: no systemic or skin reaction was registered,
and no episode of bronchospasm occurred.Discussion
AIA develops according to a clinical pattern
characterized by a sequence of symptoms3: firstly,
persistent rhinitis, then asthma, ASA intolerance,
and finally nasal polyposis appear. After the
occurrence of rhinitis, it is important to precise
AIA because such a particular asthma has to be
considered a ‘‘difficult’’ asthma which frequently
requires systemic steroids to control symptoms.There is no in vitro test for identification of ASA
intolerance, and the diagnosis can be only con-
firmed by oral24 or by inhalation25,26 ASA provoca-
tion test. Both these procedures have several
limits: while the oral test can sometimes precipi-
tate a severe asthmatic reaction, the inhalation of
increasing concentrations of L-ASA solution is
considered as unsuitable for patients whose asthma
is not in clinical remission and whose FEV1 is lower
than 70% of predicted value.
At present, NPT is regarded as the method of
choice for assessing AIA in ASA-intolerant subjects
by means of anterior rhinomanometry,19 or AR,20,21
or by measuring peak nasal inspiratory flow, which
has been shown to offer a greater reproducibility
than AR.27
In the present study, NPT confirmed as a test
simple and rapid to perform, and highly safe for
diagnosing AIA; it should then represent the
method of choice to check the hypersensitivity to
ASA which manifested by symptoms of upper
ARTICLE IN PRESS
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the older and usual diagnostic approach, NPT, when
based on the assessment of ASA-induced acoustic
rhinomanometrical changes, consented the abso-
lute protection of lung function. For these reasons,
this novel procedure should be used more widely as
the first-line diagnostic approach to the diagnosis
of hypersensitivity to ASA also in patients with
instability of the bronchial tree, and when bron-
chial or oral provocation test with ASA cannot be
carried out for safety reasons.
Several observations are supporting the hypoth-
esis that LTs may mediate AIA5–10; in particular it
has been assessed a mean fourfold increase in
urinary LTE4 levels 3–6 h following ASA ingestion,
14
and after inhalation of L-ASA.17 Moreover, the
severity of respiratory reactions during oral ASA
challenge was associated with the degree of
elevation of baseline LTE4 expression,
15 thus sug-
gesting that asthmatics with ASA-sensitive respira-
tory disorders have a spectrum of reactions in which
leukotrienes seem to play a crucial role. Despite
these observations, changes in urinary LTE4 follow-
ing NPTwith ASA were never previously investigated
in ASA-tolerant and -intolerant asthmatics.
As reported in previous studies,14–17 also the basal
elevation of urinary LTE4 excretion seems to char-
acterize and discriminate ASA-sensitive asthmatics
from non-sensitive controls. Urinary LTE4 excretion is
significantly enhanced after the simple nasal instilla-
tion of L-ASA, thus emphasizing the great diagnostic
value of LTE4 measurements even in the absence of
systemic reactions. Since even at baseline the cysLTs
production is enhanced in ASA-intolerant asthmatics,
anti-leukotriene therapy could be an option for these
type of asthmatics. This condition in fact proved
mainly sensitive to a therapeutic course with
Montelukast, a specific LT1 receptor antagonist.
28
Montelukast improved also nasal function and nasal
response to ASA in ASA-sensitive asthmatics.21,29
Moreover, despite age and lung function (FEV1),
the extent of basal LTE4 urinary excretion seems
clearly related to basal (such as pre-NPT) nasal
function, in particular to nasal volume. The crucial
role of LTE4 production (which is already exalted in
baseline) and of nasal structural involvement (i.e
nasal hyperresponsiveness) can be regarded as a
substantial contribution to the early definition of the
biological and functional pattern of ASA intolerance.Conclusions
Data of the present study further support the
diagnostic relevance of basal LTE4 measurementsand of nasal investigation in patients suspected of
ASA intolerance, thus emphasizing the intrinsic
predisposition to LTs-mediated reactivity to ASA.
Even though further studies are needed to confirm
present pilot data, NPT with L-ASA, when imple-
mented with the AR and urinary LTE4 measures,
confirms as a test absolutely safe and discriminant
for patients suspected of ASA intolerance, and
represents a suitable diagnostic procedure in the
absence of meaningful bronchial obstruction.References
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